Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

NPM1 (Nucleophosmin 1)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

›

NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: B - Late Trials venetoclax Sensitive : B	venetoclax Sensitive: B - Late Trials venetoclax Sensitive : B
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	cytarabine Sensitive: B - Late Trials cytarabine Sensitive : B	cytarabine Sensitive: B - Late Trials cytarabine Sensitive : B
FLT3‐ITD + NPM1 mutation	Acute Myelogenous Leukemia	FLT3‐ITD + NPM1 mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: B - Late Trials gilteritinib Sensitive : B	gilteritinib Sensitive: B - Late Trials gilteritinib Sensitive : B
FLT3‐ITD mutation + DNMT3A mutation + NPM1 mutation	Acute Myelogenous Leukemia	FLT3‐ITD mutation + DNMT3A mutation + NPM1 mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: B - Late Trials gilteritinib Sensitive : B	gilteritinib Sensitive: B - Late Trials gilteritinib Sensitive : B
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	azacitidine Sensitive: B - Late Trials azacitidine Sensitive : B	azacitidine Sensitive: B - Late Trials azacitidine Sensitive : B
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	revumenib Sensitive: B - Late Trials revumenib Sensitive : B	revumenib Sensitive: B - Late Trials revumenib Sensitive : B
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin hydrochloride Sensitive: C2 – Inclusion Criteria cytarabine + idarubicin hydrochloride Sensitive : C2	cytarabine + idarubicin hydrochloride Sensitive: C2 – Inclusion Criteria cytarabine + idarubicin hydrochloride Sensitive : C2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	dactinomycin Sensitive: C2 – Inclusion Criteria dactinomycin Sensitive : C2	dactinomycin Sensitive: C2 – Inclusion Criteria dactinomycin Sensitive : C2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	GS-9973 Sensitive: C2 – Inclusion Criteria GS-9973 Sensitive : C2	GS-9973 Sensitive: C2 – Inclusion Criteria GS-9973 Sensitive : C2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	sorafenib Sensitive: C2 – Inclusion Criteria sorafenib Sensitive : C2	sorafenib Sensitive: C2 – Inclusion Criteria sorafenib Sensitive : C2
NPM1 mutation	Leukemia	NPM1 mutation	Leukemia	revumenib Sensitive: C2 – Inclusion Criteria revumenib Sensitive : C2	revumenib Sensitive: C2 – Inclusion Criteria revumenib Sensitive : C2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	azacitidine Sensitive: C2 – Inclusion Criteria azacitidine Sensitive : C2	azacitidine Sensitive: C2 – Inclusion Criteria azacitidine Sensitive : C2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	KO-539 Sensitive: C2 – Inclusion Criteria KO-539 Sensitive : C2	KO-539 Sensitive: C2 – Inclusion Criteria KO-539 Sensitive : C2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	venetoclax + DS-1594 Sensitive: C2 – Inclusion Criteria venetoclax + DS-1594 Sensitive : C2	venetoclax + DS-1594 Sensitive: C2 – Inclusion Criteria venetoclax + DS-1594 Sensitive : C2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
NPM1 mutation + SRSF2 mutation + FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation	Acute Myelogenous Leukemia	NPM1 mutation + SRSF2 mutation + FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin Sensitive: C3 – Early Trials cytarabine + idarubicin Sensitive : C3	cytarabine + idarubicin Sensitive: C3 – Early Trials cytarabine + idarubicin Sensitive : C3
NPM1 mutation + SRSF2 mutation	Acute Myelogenous Leukemia	NPM1 mutation + SRSF2 mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin Sensitive: C3 – Early Trials cytarabine + idarubicin Sensitive : C3	cytarabine + idarubicin Sensitive: C3 – Early Trials cytarabine + idarubicin Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin Sensitive: C3 – Early Trials cytarabine + idarubicin Sensitive : C3	cytarabine + idarubicin Sensitive: C3 – Early Trials cytarabine + idarubicin Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
NPM1 mutation + FLT3-ITD mutation + TET2 mutation + CUX1 mutation	Acute Myelogenous Leukemia	NPM1 mutation + FLT3-ITD mutation + TET2 mutation + CUX1 mutation	Acute Myelogenous Leukemia	KO-539 Sensitive: C3 – Early Trials KO-539 Sensitive : C3	KO-539 Sensitive: C3 – Early Trials KO-539 Sensitive : C3
NPM1 mutation + DNMT3A mutation + KMT2D mutation	Acute Myelogenous Leukemia	NPM1 mutation + DNMT3A mutation + KMT2D mutation	Acute Myelogenous Leukemia	KO-539 Sensitive: C3 – Early Trials KO-539 Sensitive : C3	KO-539 Sensitive: C3 – Early Trials KO-539 Sensitive : C3
FLT3 mutation + NPM1 mutation	Acute Myelogenous Leukemia	FLT3 mutation + NPM1 mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: C3 – Early Trials gilteritinib Sensitive : C3	gilteritinib Sensitive: C3 – Early Trials gilteritinib Sensitive : C3
NPM1 mutation	Chronic Myelomonocytic Leukemia	NPM1 mutation	Chronic Myelomonocytic Leukemia	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3
NPM1 mutation	Myelodysplastic Syndrome	NPM1 mutation	Myelodysplastic Syndrome	decitabine Sensitive: C3 – Early Trials decitabine Sensitive : C3	decitabine Sensitive: C3 – Early Trials decitabine Sensitive : C3
NPM1 mutation + FLT3-TKD mutation	Acute Myelogenous Leukemia	NPM1 mutation + FLT3-TKD mutation	Acute Myelogenous Leukemia	midostaurin Sensitive: C3 – Early Trials midostaurin Sensitive : C3	midostaurin Sensitive: C3 – Early Trials midostaurin Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3
Chr t(2;5)(p23;q35) NPM1/ALK	Non-Hodgkin’s Lymphoma	Chr t(2;5)(p23;q35) NPM1/ALK	Non-Hodgkin’s Lymphoma	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3
NPM1 mutation + DNMT3A mutation	Acute Myelogenous Leukemia	NPM1 mutation + DNMT3A mutation	Acute Myelogenous Leukemia	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3
NPM1 mutation + NRAS mutation	Acute Myelogenous Leukemia	NPM1 mutation + NRAS mutation	Acute Myelogenous Leukemia	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3
FLT3 mutation + NPM1 mutation	Acute Myelogenous Leukemia	FLT3 mutation + NPM1 mutation	Acute Myelogenous Leukemia	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	venetoclax + ruxolitinib Sensitive: C3 – Early Trials venetoclax + ruxolitinib Sensitive : C3	venetoclax + ruxolitinib Sensitive: C3 – Early Trials venetoclax + ruxolitinib Sensitive : C3